Disordered mineral metabolism produced by ketogenic diet therapy.
Vitamin D and mineral metabolism status was examined in five children maintained chronically on combined ketogenic diet-anticonvulsant drug therapy (KG), and the results compared to those obtained in 18 patients treated with anticonvulsant drugs alone (AD) and 15 normal controls. KG patients exhibited biochemical findings of vitamin D deficiency osteomalacia: decreased serum 25-hydroxyvitamin D (25OHD) and calcium concentrations, elevated serum alkaline phosphatase and parathyroid hormone concentrations, decreased urinary calcium and increased urinary hydroxyproline excretion, and decreased bone mass. Although the KG and AD groups demonstrated similar reductions in serum 25OHD concentration, the KG patients exhibited a significantly greater reduction in bone mass. In response to vitamin D supplementation (5000 IU/day), mean bone mass in the KG group increased by 8.1 +/- 0.9% (P less than 0.001) over a 12-month period. These results suggest that ketogenic diet and anticonvulsant drug therapy have additive deleterious effects on bone mass and that these effects are partially reversible by vitamin D treatment.
D000138:Acidosis / Q000139:chemically induced*; D000293:Adolescent; D000469:Alkaline Phosphatase / Q000097:blood; D000927:Anticonvulsants / Q000009:adverse effects; D001842:Bone and Bones / Q000473:pathology; D002118:Calcium / Q000097:blood / Q000652:urine; D002648:Child; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000097:blood; D006909:Hydroxyproline / Q000652:urine; D007662:Ketosis / Q000139:chemically induced*; D008297:Male; D008903:Minerals / Q000378:metabolism*; D010018:Osteomalacia / Q000209:etiology; D012640:Seizures / Q000178:diet therapy* / Q000188:drug therapy; D014807:Vitamin D / Q000378:metabolism* / Q000627:therapeutic use
D000927:Anticonvulsants; D006887:Hydroxycholecalciferols; D008903:Minerals; D014807:Vitamin D; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium